Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Aug 14;26(2):296. doi: 10.1016/j.chom.2019.07.016. No abstract available.

2.

HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.

Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B.

Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8. doi: 10.1016/j.chom.2018.12.001. Erratum in: Cell Host Microbe. 2019 Aug 14;26(2):296.

3.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH.

PLoS One. 2018 Nov 14;13(11):e0205139. doi: 10.1371/journal.pone.0205139. eCollection 2018.

4.

Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate.

Bendapudi PK, Robbins A, LeBoeuf N, Pozdnyakova O, Bhatt A, Duke F, Sells R, McQuiston J, Humrighouse B, Rouaisnel B, Colling M, Stephenson KE, Saavedra A, Losman JA.

Blood Adv. 2018 Nov 13;2(21):2917-2921. doi: 10.1182/bloodadvances.2018024430. No abstract available.

5.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).

Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, Michael NL, Peter L, Nkolola JP, Borducchi EN, Chandrashekar A, Jetton D, Stephenson KE, Li W, Korber B, Tomaras GD, Montefiori DC, Gray G, Frahm N, McElrath MJ, Baden L, Johnson J, Hutter J, Swann E, Karita E, Kibuuka H, Mpendo J, Garrett N, Mngadi K, Chinyenze K, Priddy F, Lazarus E, Laher F, Nitayapan S, Pitisuttithum P, Bart S, Campbell T, Feldman R, Lucksinger G, Borremans C, Callewaert K, Roten R, Sadoff J, Scheppler L, Weijtens M, Feddes-de Boer K, van Manen D, Vreugdenhil J, Zahn R, Lavreys L, Nijs S, Tolboom J, Hendriks J, Euler Z, Pau MG, Schuitemaker H.

Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.

6.

Therapeutic vaccination for HIV: hopes and challenges.

Stephenson KE.

Curr Opin HIV AIDS. 2018 Sep;13(5):408-415. doi: 10.1097/COH.0000000000000491. Review.

PMID:
29957615
7.

Zika virus vaccines.

Abbink P, Stephenson KE, Barouch DH.

Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7. Review.

8.

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys.

Kang ZH, Bricault CA, Borducchi EN, Stephenson KE, Seaman MS, Pau M, Schuitemaker H, van Manen D, Wegmann F, Barouch DH.

J Virol. 2018 Jul 17;92(15). pii: e00537-18. doi: 10.1128/JVI.00537-18. Print 2018 Aug 1.

9.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group .

J Infect Dis. 2018 Jul 13;218(4):633-644. doi: 10.1093/infdis/jiy212.

10.

Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.

Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH.

J Virol. 2018 Jun 13;92(13). pii: e00369-18. doi: 10.1128/JVI.00369-18. Print 2018 Jul 1.

11.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

12.

Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function.

Larocca RA, Provine NM, Aid M, Iampietro MJ, Borducchi EN, Badamchi-Zadeh A, Abbink P, Ng'ang'a D, Bricault CA, Blass E, Penaloza-MacMaster P, Stephenson KE, Barouch DH.

Sci Immunol. 2016 Nov;1(5). pii: eaaf7643. doi: 10.1126/sciimmunol.aaf7643. Epub 2016 Nov 4.

13.

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng'ang'a D, Nkolola JP, Brinkman AL, Peter L, Lee BC, Jimenez J, Jetton D, Mondesir J, Mojta S, Chandrashekar A, Molloy K, Alter G, Gerold JM, Hill AL, Lewis MG, Pau MG, Schuitemaker H, Hesselgesser J, Geleziunas R, Kim JH, Robb ML, Michael NL, Barouch DH.

Nature. 2016 Dec 8;540(7632):284-287. doi: 10.1038/nature20583. Epub 2016 Nov 9.

14.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng'ang'a D, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Agarwal A, Brinkman AL, Cabral C, Chandrashekar A, Giglio PB, Jetton D, Jimenez J, Lee BC, Mojta S, Molloy K, Shetty M, Neubauer GH, Stephenson KE, Peron JP, Zanotto PM, Misamore J, Finneyfrock B, Lewis MG, Alter G, Modjarrad K, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Science. 2016 Sep 9;353(6304):1129-32. doi: 10.1126/science.aah6157. Epub 2016 Aug 4.

15.

Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy.

Stephenson KE, Neubauer GH, Bricault CA, Shields J, Bayne M, Reimer U, Pawlowski N, Knaute T, Zerweck J, Seaman MS, Rosenberg ES, Barouch DH.

Open Forum Infect Dis. 2016 May 19;3(2):ofw100. doi: 10.1093/ofid/ofw100. eCollection 2016 Apr.

16.

New concepts in HIV-1 vaccine development.

Stephenson KE, D'Couto HT, Barouch DH.

Curr Opin Immunol. 2016 Aug;41:39-46. doi: 10.1016/j.coi.2016.05.011. Epub 2016 Jun 3. Review.

17.

Broadly Neutralizing Antibodies for HIV Eradication.

Stephenson KE, Barouch DH.

Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7. doi: 10.1007/s11904-016-0299-7. Review.

18.

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization.

Maxfield LF, Abbink P, Stephenson KE, Borducchi EN, Ng'ang'a D, Kirilova MM, Paulino N, Boyd M, Shabram P, Ruan Q, Patel M, Barouch DH.

Clin Vaccine Immunol. 2015 Nov;22(11):1166-75. doi: 10.1128/CVI.00510-15. Epub 2015 Sep 16.

19.

Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development.

Stephenson KE, Neubauer GH, Reimer U, Pawlowski N, Knaute T, Zerweck J, Korber BT, Barouch DH.

J Immunol Methods. 2015 Jan;416:105-23. doi: 10.1016/j.jim.2014.11.006. Epub 2014 Nov 15.

20.

Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys.

Li H, Stephenson KE, Kang ZH, Lavine CL, Seaman MS, Barouch DH.

J Virol. 2014 Nov;88(22):13510-5. doi: 10.1128/JVI.02095-14. Epub 2014 Sep 10.

21.

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, Liu J, Abbink P, Maxfield LF, Seaman MS, Dugast AS, Alter G, Ferguson M, Li W, Earl PL, Moss B, Giorgi EE, Szinger JJ, Eller LA, Billings EA, Rao M, Tovanabutra S, Sanders-Buell E, Weijtens M, Pau MG, Schuitemaker H, Robb ML, Kim JH, Korber BT, Michael NL.

Cell. 2013 Oct 24;155(3):531-9. doi: 10.1016/j.cell.2013.09.061. Epub 2013 Oct 24.

22.

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR.

Nature. 2013 Nov 14;503(7475):224-8. doi: 10.1038/nature12744. Epub 2013 Oct 30.

23.

A global approach to HIV-1 vaccine development.

Stephenson KE, Barouch DH.

Immunol Rev. 2013 Jul;254(1):295-304. doi: 10.1111/imr.12073. Review.

24.

Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys.

Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, Korber B, Barouch DH.

J Virol. 2012 Nov;86(21):11434-40. doi: 10.1128/JVI.01779-12. Epub 2012 Aug 15.

25.

Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys.

Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH.

J Virol. 2012 Sep;86(18):9583-9. doi: 10.1128/JVI.00996-12. Epub 2012 Jul 3.

26.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH.

J Infect Dis. 2012 Jun 15;205(12):1806-10. doi: 10.1093/infdis/jis285. Epub 2012 Apr 5.

27.

Internet-enabled thyroid hormone abuse.

Neuberg GW, Stephenson KE, Sears DA, McConnell RJ.

Ann Intern Med. 2009 Jan 6;150(1):60-1. No abstract available.

PMID:
19124828
28.

Recurrent acute pancreatitis in anorexia and bulimia.

Morris LG, Stephenson KE, Herring S, Marti JL.

JOP. 2004 Jul;5(4):231-4.

29.

Clinical experience and choice of drug therapy for human immunodeficiency virus disease.

Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI.

Clin Infect Dis. 1999 Jan;28(1):14-22.

PMID:
10028063
30.

Measurements of relative angular distributions for the 2H

Stephenson KE, Holt RJ, McKeown RD, Specht aJ.

Phys Rev C Nucl Phys. 1987 Jun;35(6):2023-2027. No abstract available.

PMID:
9953998

Supplemental Content

Loading ...
Support Center